Japanese pharmaceutical giant Takeda Pharmaceuticals (TYO: 4502 / NYSE: TAK) has confirmed reports from Nikkei that it is planning to eliminate approximately 1,000 positions in the United States. This move is part of a strategic downsizing that will see the closure of a research facility in San Diego, California, and job reductions at multiple other US locations.
In May 2024, Takeda unveiled a ‘multi-year program’ aimed at bolstering profit margins and enhancing the company’s agility. The initiative comes in response to the financial pressures caused by the expiration of patents on several key products, which has led to a decline in profit margins. The comprehensive plan encompasses optimization of the workforce and corporate structure, as well as stringent decision-making regarding pipeline prioritization.- Flcube.com
